|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,486,428: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,486,428, granted on November 8, 2016, to Amgen Inc., pertains to a novel class of antibody formulations and their methods of use, primarily targeting inflammatory and autoimmune diseases. The patent claims encompass specific monoclonal antibodies, their compositions, and therapeutic methods of administration, notably emphasizing modifications that enhance stability, efficacy, or pharmacokinetic profiles.
This analysis dissects the patent's scope and claims, contextualizing its position within the broader therapeutic antibody landscape. It also reviews relevant prior art, technological trends, and patent landscape implications, equipping stakeholders with knowledge to assess freedom-to-operate, licensing opportunities, or competitive positioning.
1. Patent Overview
| Patent Details |
Information |
| Patent Number |
9,486,428 |
| Filing Date |
July 24, 2014 |
| Issue Date |
November 8, 2016 |
| Assignee |
Amgen Inc. |
| Title |
"Anti-IL-17 antibodies and methods of use" |
| Jurisdiction |
United States |
Key Innovations
- Monoclonal antibodies specifically binding to interleukin-17 (IL-17).
- Variants with modifications conferring increased stability or altered pharmacokinetics.
- Methods for treating autoimmune disorders such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
2. Scope and Claims Analysis
2.1. Claims Overview
The patent comprises independent claims and multiple dependent claims spanning:
- Specific amino acid sequences of antibodies.
- Variants with amino acid mutations.
- Pharmaceutical compositions containing these antibodies.
- Methods of treating IL-17 mediated diseases.
| Claim Type |
Number of Claims |
Scope Summary |
| Independent Claims |
3 |
Define the antibody molecules with particular variable region sequences and their use in therapy. |
| Dependent Claims |
30+ |
Cover modifications, formulations, dosing regimens, and specific disease indications. |
2.2. Key Independent Claims
| Claim Number |
Content Summary |
Scope |
| Claim 1 |
An isolated monoclonal antibody comprising heavy and light chain variable regions with specific sequences as set forth. |
Antibody molecule with defined VH and VL sequences targeting IL-17. |
| Claim 2 |
A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. |
Formulation claims. |
| Claim 3 |
A method of treating an IL-17 mediated disorder in a patient, comprising administering an effective amount of the antibody of claim 1. |
Therapeutic use claims. |
2.3. Scope of the Antibody Claims
The core antibodies are anti-IL-17A monoclonal antibodies with sequences disclosed explicitly in the specification, including:
- Heavy chain variable region (VH) sequences.
- Light chain variable region (VL) sequences.
- Specific complementarity-determining regions (CDRs).
Modified variants with amino acid substitutions within the CDRs or framework regions are also covered, emphasizing enhancing stability or reduced immunogenicity.
2.4. Limitations and Expansions
- The claims encompass both the full antibody molecules and fragments (e.g., Fab, scFv).
- The patent also discusses bivalent and bispecific formats, broadening the scope to similar formats engaging IL-17.
- The therapeutic methods claimed involve administering antibodies at specified doses and regimens.
3. Patent Landscape Context
3.1. Prior Art Landscape
The patent cites substantial prior art, particularly:
| Prior Art Reference |
Relevance |
Key Features Addressed |
| U.S. Pat. No. 8,600,345 (Amgen, 2013) |
Anti-IL-17 monoclonal antibodies |
Early work on IL-17 targeting antibodies, including secukinumab. |
| WO 2010/009599 |
IL-17 inhibitors |
Details on antibody sequences and formulations. |
| US 8,679,621 |
Humanized anti-IL-17 antibodies |
Variants with enhanced properties. |
The patent references existing anti-IL-17 antibodies, notably secukinumab (marketed by Novartis), highlighting the need for differentiation through sequence modifications or specific formulations.
3.2. Innovation Positioning
- The patent delineates specific novel variable region sequences, differentiating from prior art anti-IL-17 antibodies.
- Emphasizes method claims that cover treatment protocols, not just molecular claims.
- Focus on stability and manufacturability, which are crucial for commercial development.
3.3. Overlap and Potential Litigation Risks
- The scope of sequence claims may face challenges based on prior art antibodies.
- The inclusion of variant sequences introduces patent thicket considerations.
- The landscape is crowded with IL-17 antagonists, competing via patent exclusivity, especially in therapeutic indications.
3.4. Strategic Positioning for Stakeholders
- Amgen's patent offers a narrow but strategic claim suite on specific antibody sequences.
- It fortifies Amgen’s position in IL-17 biology, especially if the sequences confer advantages over competitors.
- Companies developing biosimilar or biosimilar-like products must scrutinize these claims for potential infringement.
4. Therapeutic and Commercial Implications
| Aspect |
Details |
| Target Diseases |
Psoriasis, psoriatic arthritis, ankylosing spondylitis, other IL-17 related inflammatory disorders. |
| Competitive Landscape |
Existing drugs: secukinumab (Cosentyx), ixekizumab (Taltz). Amgen's patent may secure a share if sequence innovations provide differentiation. |
| Patent Duration |
Expected expiration around 2034–2036, considering patent term adjustments and maintenance. |
| Potential Challenges |
Obviousness rejections based on prior IL-17 antibodies; patent invalidation if prior art outweighs novelty. |
| Lifecycle Strategy |
Leverage claims to expand patent coverage through further innovations or filings on formulations, delivery methods, or combination therapies. |
5. Comparative Analysis: Amgen's Patent vs. Market Leaders
| Parameter |
U.S. Patent 9,486,428 |
Secukinumab (Cosentyx) |
Ixekizumab (Taltz) |
| Type |
Sequence-specific monoclonal antibody |
Approved monoclonal antibody targeting IL-17A |
Similar to secukinumab, targeting IL-17A |
| Innovation |
Specific VH and VL sequences, variants |
Naturally occurring or humanized antibodies |
Similar binding epitopes, different sequences |
| Claims Focus |
Molecular sequences and methods of use |
Use patents, compound patents |
Use and composition patents |
| Patents Expiry (Approximate) |
2034–2036 |
2024–2038 (depending on extensions) |
2024–2038 |
Amgen's patent positions itself as a sequence-specific alternative, potentially offering a basis for manufacturing or bioequivalence claims.
6. Deep-Dive Comparison: Claims Scope and Patent Claims Breadth
| Aspect |
Amgen '428' Patent |
Competitor Patent Portfolio |
| Claim Breadth |
Focused on specific VH and VL sequences; includes variants |
Broad claims on anti-IL-17 antibodies; often encompassing multiple sequences |
| Claim Focus |
Sequence determinacy; specific mutations to improve properties |
Functional binding and therapeutic effect |
| Innovative Scope |
Molecular identity and modifications |
Functionality and use-based claims |
Conclusion: Amgen’s patent emphasizes molecular specificity, providing strong protection if the sequences are novel and non-obvious over prior art.
7. Key Trends and Patent Strategies in IL-17 Antibody Space
| Trend |
Description |
Implication |
| Sequence Patents |
Focus on defining unique variable regions |
Competitive differentiation and blocking patenting of clones |
| Formulation Patents |
Stabilization, delivery, and dosage |
Protects manufacturing methods and delivery systems |
| Combination Therapies |
Using IL-17 antibodies with other biologics |
Expands patent landscape coverage |
| Bi-specifics and Fragment Variants |
Next-generation formats targeting IL-17 |
Broadens scope beyond traditional monoclonals |
Stakeholders should monitor filings and maturity of these innovations to maintain strategic advantage.
8. Conclusions and Recommendations
-
Patent Scope: U.S. Patent 9,486,428 provides detailed claims on specific anti-IL-17 monoclonal antibodies with defined sequences, including variants, formulations, and methods of use. Its narrow molecular claims complement broader method claims, positioning Amgen strategically within the anti-IL-17 space.
-
Competitive Landscape: Amgen’s patent acts as a defensive patent, securing molecular claims against biosimilars and competitors, especially in jurisdictions where these antibodies are being developed or commercialized.
-
Infringement Risks: Developers of anti-IL-17 antibodies with similar sequences or formulations must assess potential infringement, especially concerning the specific sequences disclosed.
-
Innovation Opportunities: Future patent filings might focus on novel modifications, delivery methods, combination therapies, or bispecific constructs, potentially extending the patent estate.
-
Legal and Market Strategy: Maintaining patent integrity involves monitoring prior art and evolving the claims to cover emerging antibody formats and indications.
Key Takeaways
-
U.S. Patent 9,486,428 establishes strong molecular claims on specific anti-IL-17 monoclonal antibodies, supporting Amgen's position in the autoimmune therapeutic landscape.
-
The patent landscape is highly competitive, with existing approvals for similar biologics and ongoing patent filings on sequence variants and innovative formulations.
-
Developers should scrutinize the specific sequences and claims to ensure freedom-to-operate or to seek licensing opportunities.
-
Patents covering antibody sequences are vulnerable if those sequences are found in prior art; thus, continuous prosecution and strategic filings are critical.
-
Expanding patent coverage through formulations, delivery mechanisms, or combination therapies remains essential for maximizing lifecycle and market exclusivity.
FAQs
Q1: How does U.S. Patent 9,486,428 differentiate from other anti-IL-17 patents?
A1: It explicitly claims specific amino acid sequences of the antibody’s variable regions, providing molecular-level protection, whereas other patents may focus on functional or use-based claims, thus offering narrower but potentially more defensible coverage.
Q2: Can other companies develop anti-IL-17 antibodies with similar sequences without infringing?
A2: Only if their sequences are sufficiently dissimilar or if they do not fall within the scope of the patent claims. Detailed sequence comparison and legal analysis are necessary.
Q3: What is the significance of the variant claims in this patent?
A3: They cover modifications, such as amino acid substitutions, allowing protection against minor alterations that could be used to circumvent the patent.
Q4: How long does patent protection for this antibody last?
A4: Assuming standard term calculations and no extensions, protection could extend to approximately 2034–2036, with potential extensions depending on patent term adjustments.
Q5: Are there any ongoing litigations or patent challenges related to this patent?
A5: No publicly available litigation or re-examinations have been reported as of the current date; however, patent landscapes evolve, and patent validity may be challenged based on prior art or patentability issues.
References
[1] U.S. Patent 9,486,428, "Anti-IL-17 antibodies and methods of use," Amgen Inc., issued Nov. 8, 2016.
[2] S. Gaffen, "IL-17 Family Cytokines," Immunity, 2015.
[3] N. Buhl et al., "Anti-IL-17 therapies: Current overview," Expert Opin Investig Drugs, 2019.
[4] FDA Approval Documentation for Secukinumab (Cosentyx), 2015.
[5] WIPO Patent Application WO 2010/009599, "Anti-IL-17 Antibodies," 2010.
More… ↓
⤷ Start Trial
|
